Federal Illegal Status — The Schedule I Baseline
Placeholder: federal law classifies most psychedelics as Schedule I substances.
- Schedule I: Federal schedule (Placeholder short note)
- 50: States affected (Placeholder short note)
- Few: Legal exemptions (Placeholder short note)
- Variable: Enforcement priority (Placeholder short note)
Federal prohibition framework
Placeholder: Controlled Substances Act sets the federal baseline for psychedelics.
Oregon Measure 109 — Supervised Legal Access
Placeholder: Oregon created licensed psilocybin service centers with trained facilitators.
- Measure 109: Program name (Placeholder short note)
- Growing: Licensed centers (Placeholder short note)
- Required: Facilitator training (Placeholder short note)
- Not required: Medical diagnosis (Placeholder short note)
Supervised service center structure
Placeholder: adults access supervised sessions without a medical diagnosis requirement.
Canada Special Access Program — Physician-Requested Access
Placeholder: Canada allows physicians to request psychedelic access for patients.
- SAP: Program name (Placeholder short note)
- Physician: Requestor (Placeholder short note)
- Case-by-case: Approval basis (Placeholder short note)
- End-of-life care: Typical use (Placeholder short note)
Case-by-case physician requests
Placeholder: Health Canada reviews individual patient access requests via SAP.
Decriminalization vs Legalization — A Key Distinction
Placeholder: decriminalization lowers penalties while legalization builds licensed systems.
- Criminal penalty: Decrim removes (Placeholder short note)
- Licensed market: Legalization adds (Placeholder short note)
- Local ordinance: Example decrim city (Placeholder short note)
- Oregon: Example legal state (Placeholder short note)
Two distinct regulatory strategies
Placeholder: decrim and legalization solve different problems with different tools.
Access Pathway Comparison Across Jurisdictions
Placeholder: clinical trials, licensed centers, and SAP form distinct access routes.
- Research-only: Clinical trial route (Placeholder short note)
- Licensed center: Oregon route (Placeholder short note)
- Physician request: Canada route (Placeholder short note)
- No legal access: Federal-only route (Placeholder short note)
Comparing the four pathways
Placeholder: each pathway trades off speed, oversight, and eligibility differently.
Placeholder: no single pathway dominates — each fits different patient needs.